Literature DB >> 11511251

Synthesis of novel retinoid X receptor-selective retinoids.

M M Faul1, A M Ratz, K A Sullivan, W G Trankle, L L Winneroski.   

Abstract

Retinoids 1-5 have been identified as potent RXR agonists for evaluation in the treatment of non-insulin-dependent (type II) diabetes mellitus (NIDDM). Highly convergent syntheses of 1-5 have been developed. The core tetrahydronaphthalene 7, employed in the synthesis of 1 and 2, was prepared in 98% yield using an AlCl(3)-catalyzed (0.03 equiv) Friedel-Crafts alkylation of toluene with 2,5-dichloro-2,5-dimethylhexane 6. A nitromethane-mediated Fridel-Crafts acylation of 7 with chloromethylnicotinate 9 was developed to prepare ketone 10 in 68% yield. Chelate-controlled addition of MeMgCl to 10 followed by dehydration afforded olefin 11 in 65% yield. Cyclopropanation of 11 with trimethylsulfoxonium ylide, followed by saponification, completed a five-step synthesis of 1 in 33% yield. FeCl(3)-catalyzed (0.05 equiv) Friedel-Crafts acylation of 7 with chloromethylterephthalate 14 afforded ketone 15 in 81% yield. Saponification of 15 and reaction with 50% aqueous NH(2)OH in AcOH afforded a 9:1 mixture of cis and trans oximes, from which the desired cis-oxime 2 was isolated in 43% yield. The core bromo-dihydronaphthalene 29 required for the synthesis of 3-5 was prepared by a Shapiro reaction. Transmetalation of 29 and reaction with Weinreb amides 30b or 36 afforded ketones 32 and 37, which were converted into 3-5 using chemistry comparable to the tetrahydronaphthylene series. Suzuki coupling of boronic acids 41 and 42 with vinyl triflate 43 provided an alternative approach to the synthesis of this class of compounds.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11511251     DOI: 10.1021/jo0103064

Source DB:  PubMed          Journal:  J Org Chem        ISSN: 0022-3263            Impact factor:   4.354


  9 in total

1.  Synthesis and biological evaluation of retinoid-chalcones as inhibitors of colon cancer cell growth.

Authors:  Cassia S Mizuno; Shiby Paul; Nanjoo Suh; Agnes M Rimando
Journal:  Bioorg Med Chem Lett       Date:  2010-10-14       Impact factor: 2.823

2.  β-Selective Reductive Coupling of Alkenylpyridines with Aldehydes and Imines via Synergistic Lewis Acid/Photoredox Catalysis.

Authors:  Katarzyna N Lee; Zhen Lei; Ming-Yu Ngai
Journal:  J Am Chem Soc       Date:  2017-03-30       Impact factor: 15.419

3.  Chemoselective synthesis of ketones and ketimines by addition of organometallic reagents to secondary amides.

Authors:  William S Bechara; Guillaume Pelletier; André B Charette
Journal:  Nat Chem       Date:  2012-02-21       Impact factor: 24.427

4.  Creation and discovery of ligand-receptor pairs for transcriptional control with small molecules.

Authors:  Lauren J Schwimmer; Priyanka Rohatgi; Bahareh Azizi; Katherine L Seley; Donald F Doyle
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-29       Impact factor: 11.205

5.  Modeling, synthesis and biological evaluation of potential retinoid X receptor-selective agonists: novel halogenated analogues of 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (bexarotene).

Authors:  Julie K Furmick; Ichiro Kaneko; Angela N Walsh; Joanna Yang; Jaskaran S Bhogal; Geoffrey M Gray; Juan C Baso; Drew O Browder; Jessica L S Prentice; Luis A Montano; Chanh C Huynh; Lisa M Marcus; Dorian G Tsosie; Jungeun S Kwon; Alexis Quezada; Nicole M Reyes; Brittney Lemming; Puneet Saini; Arjan van der Vaart; Thomas L Groy; Pamela A Marshall; Peter W Jurutka; Carl E Wagner
Journal:  ChemMedChem       Date:  2012-09       Impact factor: 3.466

6.  Amyloid-β pathology and APOE genotype modulate retinoid X receptor agonist activity in vivo.

Authors:  Leon M Tai; Kevin P Koster; Jia Luo; Sue H Lee; Yue-Ting Wang; Nicole C Collins; Manel Ben Aissa; Gregory R J Thatcher; Mary Jo LaDu
Journal:  J Biol Chem       Date:  2014-09-12       Impact factor: 5.157

7.  Modeling, synthesis and biological evaluation of potential retinoid X receptor (RXR) selective agonists: novel analogues of 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (bexarotene).

Authors:  Carl E Wagner; Peter W Jurutka; Pamela A Marshall; Thomas L Groy; Arjan van der Vaart; Joseph W Ziller; Julie K Furmick; Mark E Graeber; Erik Matro; Belinda V Miguel; Ivy T Tran; Jungeun Kwon; Jamie N Tedeschi; Shahram Moosavi; Amina Danishyar; Joshua S Philp; Reina O Khamees; Jevon N Jackson; Darci K Grupe; Syed L Badshah; Justin W Hart
Journal:  J Med Chem       Date:  2009-10-08       Impact factor: 7.446

8.  Modeling, synthesis, and biological evaluation of potential retinoid X receptor (RXR) selective agonists: novel analogues of 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (bexarotene) and (E)-3-(3-(1,2,3,4-tetrahydro-1,1,4,4,6-pentamethylnaphthalen-7-yl)-4-hydroxyphenyl)acrylic acid (CD3254).

Authors:  Peter W Jurutka; Ichiro Kaneko; Joanna Yang; Jaskaran S Bhogal; Johnathon C Swierski; Christa R Tabacaru; Luis A Montano; Chanh C Huynh; Rabia A Jama; Ryan D Mahelona; Joseph T Sarnowski; Lisa M Marcus; Alexis Quezada; Brittney Lemming; Maria A Tedesco; Audra J Fischer; Said A Mohamed; Joseph W Ziller; Ning Ma; Geoffrey M Gray; Arjan van der Vaart; Pamela A Marshall; Carl E Wagner
Journal:  J Med Chem       Date:  2013-11-01       Impact factor: 7.446

9.  Modeling, Synthesis, and Biological Evaluation of Potential Retinoid-X-Receptor (RXR) Selective Agonists: Analogs of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahyro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene) and 6-(Ethyl(4-isobutoxy-3-isopropylphenyl)amino)nicotinic Acid (NEt-4IB).

Authors:  Peter W Jurutka; Orsola di Martino; Sabeeha Reshi; Sanchita Mallick; Zhela L Sabir; Lech J P Staniszewski; Ankedo Warda; Emma L Maiorella; Ani Minasian; Jesse Davidson; Samir J Ibrahim; San Raban; Dena Haddad; Madleen Khamisi; Stephanie L Suban; Bradley J Dawson; Riley Candia; Joseph W Ziller; Ming-Yue Lee; Chang Liu; Wei Liu; Pamela A Marshall; John S Welch; Carl E Wagner
Journal:  Int J Mol Sci       Date:  2021-11-16       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.